Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car
A phase 2/3 trial of Pembrolizumab in merkel cell carcinoma, run by TuHURA Biosciences, Inc., now recruiting.
Overview
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma is a phase 2/3 interventional study registered as NCT06947928 by TuHURA Biosciences, Inc., with 118 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: IFx-Hu2.0, Placebo, Pembrolizumab. Conditions listed: Advanced Or Metastatic Merkel Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Shares Merkel cell carcinoma, Pembrolizumab.
- TrialSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Shares Merkel cell carcinoma, Pembrolizumab.
- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Merkel cell carcinoma, Pembrolizumab.
- CancerSkin cancer (all types)
Shares Merkel cell carcinoma, Pembrolizumab.